Methods and compositions for treating metabolic disorders

• US 20090143279A1
• Filed: 06/13/2008
• Published: 06/04/2009
• Est. Priority Date: 06/15/2007
• Status: Abandoned Application

• Current Assignee: President and Fellows of Harvard College (Harvard Corporation)
• Original Assignee: President and Fellows of Harvard College (Harvard Corporation)
• Inventors: Mootha, Vamsi Krishna, Kitami, Toshimori, Wagner, Bridget
• Application Number:
  US12/157,824
• Publication Number:
  US 20090143279A1
• Time in Patent Office: Days
• US Class Current: 514/1.100
• CPC Class Codes: A61K 31/4164 1,3-Diazoles
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

The present invention provides methods of treating of disorders characterized by defective mitochondrial activity. In particular compounds of the present invention can be used in the treatment metabolic diseases and neurodegenerative diseases. The methods are also useful to increase oxidative phosphorylation or to decrease reactive oxygen species (ROS) production in a subject in need thereof.

Claims

1. A method of treating or preventing a disorder characterized by mitochondrial dysfunction in a subject, the method comprising administering to the subject a therapeutically effective amount of a cytoskeleton modulator.

2. The method of claim 1, wherein the cytoskeleton modulator is a microtubule modulator.

3. The method of claim 2, wherein the microtubule modulator is a microtubule inhibitor.

4. The method of claim 1, wherein the cytoskeleton modulator is a compound of Formula (I):

5. The method of claim 4, wherein the compound is mebendazole, a derivative, metabolite, or analog thereof.

6. The method of claim 5, wherein the subject is not afflicted with a worm infection.

7. The method of claim 5, wherein the subject is not afflicted with diabetes.

8. The method of claim 4, wherein the compound is nocodazole, a derivative, metabolite, or analog thereof.

9. The method of claim 4, wherein the compound is one of the following:

albendazole, fenbendazole, oxfendazole, oxibendazole, methiazole, parbendazole, and any derivatives, metabolites, or analogs of the compounds listed.

10. The method of claim 1, wherein the cytoskeleton modulator is cytochalasin, a derivative, metabolite, or analog thereof.

11. The method of claim 10, wherein the cytochalasin is selected from cytochalasin A, cytochalasin B, cytochalasin C, cytochalasin D, cytochalasin E, cytochalasin F, cytochalasin H, cytochalasin J, cytochalasin K, cytochalasin Q, cytochalasin R, epoxycytochalasin H and epoxycytochalasin J.

12. The method of claim 11, wherein the cytochalasin is selected from cytochalasin E.

13. The method of claim 1, wherein the cytoskeleton modulator is a compound of Formula (II):

14. The method of claim 1, wherein the cytoskeleton modulator is a compound selected from Formulas (III)-(VI):

15. The method of claim 14, wherein the compound is deoxysappanone B, or a metabolite, or an analog thereof.

16. The method of claim 15, wherein the deoxysappanone is selected from deoxysappanone (B) 7,3′

-dimethyl ether, sappanone (A) trimethyl ether, or 3-deshydroxysappanol trimethyl ether.

17. The method of claim 15, wherein the subject is not afflicted with diabetes.

18. The method of claim 1, wherein the cytoskeleton modulator is a compound of Formula (VII):

19. The method of claim 18, wherein the compound is paclitaxel or a metabolite or analog thereof.

20. The method of claim 1, wherein the compound is podofilox, a metabolite, analog, or salt thereof.

21. The method of claim 20, wherein the compound is podophyllotoxin acetate.

22. The method of claim 1, wherein the cytoskeleton modulator is a compound of Formula (VIII):

23. The method of claim 22, wherein the compound is vinblastine or a metabolite or analog thereof.

24. The method of claim 1, wherein the mitochondrial dysfunction is characterized by reduced oxidative phosphorylation or increased generation of reactive oxygen species or both.

25. The method of claim 1, wherein the disorder is, obesity, cardiac myopathy, premature aging, coronary atherosclerotic heart disease, diabetes mellitus, Alzheimer'"'"'s Disease, Parkinson'"'"'s Disease, Huntington'"'"'s disease, dystonia, Leber'"'"'s hereditary optic neuropathy (LHON), schizophrenia, myodegenerative disorders such as “

mitochondrial encephalopathy, lactic acidosis, and stroke”

(MELAS) and “

myoclonic epilepsy ragged red fiber syndrome”

(MERRF), NARP (Neuropathy;

Ataxia;

Retinitis Pigmentosa), MNGIE (Myopathy and external opthalmoplegia, neuropathy;

gastro-intestinal encephalopathy, Kearns-Sayre disease, Pearson'"'"'s Syndrome, PEO (Progressive External Opthalmoplegia), congenital muscular dystrophy with mitochondrial structural abnormalities, Wolfram syndrome, Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy Deafness, Leigh'"'"'s Syndrome, fatal infantile myopathy with severe mitochondrial DNA (mtDNA) depletion, benign “

later-onset”

myopathy with moderate reduction in mtDNA, dystonia, medium chain acyl-CoA dehydrogenase deficiency, arthritis, and maternally inherited diabetes with deafness (MIDD), mitochondrial DNA depletion syndrome.

26. The method of claim 1, wherein the subject is not afflicted with cancer.

27. The method of claim 1, wherein the disorder is obesity.

28. The method of claim 1, wherein the disorder is diabetes.

29. The method of claim 28, wherein the diabetes is type 2 diabetes mellitus.

30. The method of claim 1, wherein the disorder is glucose intolerance.

31. The method of claim 1, wherein the subject has elevated gluconeogenesis.

32. The method of claim 1, wherein the disorder is premature aging.

33. The method of claim 1, wherein the disorder is a neurodegenerative disorder.

34. The method of claim 1, wherein the disorder is an mtDNA-associated disease.

35. The method of claim 1, wherein the disorder is a mitochondrial encephalomyopathy due to nuclear gene mutations.

36. The method of claim 1, wherein the disorder is a congenital mitochondrial disorder.

37. The method of claim 1, wherein the disorder is cardiovascular disease.

38. The method of claim 1, wherein the disorder is cardiomyopathy.

39. The method of claim 1, further comprising administering to the subject one or more agents selected from sulfonylureas, non-sulfonylurea secretagogues, insulin, insulin analogs, glucagon-like peptides, exendin-4 polypeptides, beta 3 adrenoceptor agonists, PPAR agonists, dipeptidyl peptidase IV inhibitors, biguanides, alpha-glucosidase inhibitors, immunomodulators, statins and statin-containing combinations, angiotensin converting enzyme inhibitors, adeno sine A1 receptor agonists, adenosine A2 receptor agonists, aldosterone antagonists, alpha 1 adrenoceptor antagonists, alpha 2 adrenoceptor agonists, alpha 2 adrenoceptor agonists, angiotensin receptor antagonists, antioxidants, ATPase inhibitors, atrial peptide agonists, beta adrenoceptor antagonists, calcium channel agonists, calcium channel antagonists, diuretics, dopamine D1 receptor agonists, endopeptidase inhibitors, endothelin receptor antagonists, guanylate cyclase stimulants, phosphodiesterase V inhibitors, protein kinase inhibitors, Cdc2 kinase inhibitors, renin inhibitors, thromboxane synthase inhibitors, vasopeptidase inhibitors, vasopressin I antagonists, vasopressin 2 antagonists, angiogenesis inhibitors, advanced glycation end product inhibitors, bile acid binding agents, bile acid transport inhibitors, bone formation stimulants, apolipoprotein A1 agonists, DNA topoisomerase inhibitors, cholesterol absorption inhibitors, cholesterol antagonists, cholesteryl ester transfer protein antagonists, cytokine synthesis inhibitors, DNA polymerase inhibitors, dopamine D2 receptor agonists, endothelin receptor antagonists, growth hormone antagonists, insulin sensitizers, lipase inhibitors, lipid peroxidation inhibitors, lipoprotein A antagonists, microsomal transport protein inhibitors, microsomal triglyceride transfer protein inhibitors, nitric oxide synthase inhibitors, oxidizing agents, phospholipase A2 inhibitors, radical formation agonists, platelet aggregation antagonists, prostaglandin synthase stimulants, reverse cholesterol transport activators, rho kinase inhibitors, selective estrogen receptor modulators, squalene epoxidase inhibitors, squalene synthase inhibitors, thromboxane A2 antagonists, amylin agonists, cannabinoid receptor antagonists, cholecystokinin A agonists, corticotropin-releasing factor agonists, dopamine uptake inhibitors, G protein-coupled receptor modulators, glutamate antagonists, glucagon-like peptide-1 agonists, insulin sensitizers, lipase inhibitors, melanin-concentrating hormone receptor antagonists, nerve growth factor agonists, neuropeptide Y agonists, neuropeptide Y antagonists, SNRIs, protein tyrosine phosphatase inhibitors, serotonin 2C receptor agonists, bezafibrate, diflunisal, or cinnamic acid.

40. A method for identifying compounds that enhance mitochondrial function comprising (i) assaying for the effect of one or more compounds on (a) OXPHOS gene expression and (b) mitochondrial function;

and (ii) correlating the effect with a compound'"'"'s enhancement of mitochondrial function, wherein an increase in OXPHOS gene expression and an increase in mitochondrial function is indicative of a compound that enhances mitochondrial function.

41. A method for identifying compounds for treating a disorder characterized by mitochondrial dysfunction in a subject comprising (i) assaying for the effect of one or more compounds on (a) OXPHOS gene expression and (b) mitochondrial function;

and (ii) correlating the effect with a compound'"'"'s ability to treat said disorder, wherein an increase in OXPHOS gene expression and an increase in mitochondrial function is indicative of a compound useful for treating said disorder.

42. A method for determining compounds that are contraindicated in a subject, comprising (i) assaying for the effect of one or more compounds on (a) cellular dehydrogenase activity and (b) cell viability;

and (ii) correlating the effect with contraindication of a compound, wherein a decrease in cellular dehydrogenase activity absent a decrease in cell viability indicates that the compound is contraindicated for said subjects.

43. A method for determining two or more compounds that are contraindicated for joint administration to a subject comprising (i) assaying for the effect of two or more compounds on (a) cellular dehydrogenase activity and (b) cell viability;

and (ii) correlating the effect with contraindication of joint administration, wherein two or more compounds that each decrease cellular dehydrogenase activity absent a decrease in cell viability indicates that the two or more compounds are contraindicated when jointly administered to a subject.

44. A kit comprising a plurality of primer pairs wherein each primer pair comprises a first nucleic acid sequence and a second nucleic acid sequence which first nucleic acid sequence hybridizes under stringent conditions to a first strand of a target sequence, and which second nucleic acid sequence hybridizes under stringent conditions to a second strand of a target sequence, wherein the target sequence is selected from a group consisting of the following:

(a) Mt-Atp6, (b) Mt-Atp8, (c) Mt-Co1, (d) Mt-Co2, (e) Mt-Co3, (f) Mt-Cytb, (g) Mt-Nd1, (h) Mt-Nd2, (i) Mt-Nd3, (j) Mt-Nd4, (k) Mt-Nd41, (l) Mt-Nd5, (m) Mt-Nd61, (n) Atp5a1, (o) Atp5c1, (p) Atp5o, (q) Cox5b, (r) Cox7a2, (s) Cyc1, (t) Hspc051, (u) Ndufa5, (v) Ndufb5, (w) Sdhd, (x) Uqcrb, and (y) Uqcrc1.

45. The kit of claim 44, wherein each first nucleic acid and/or the second nucleic acid further comprises a tag sequence.

46. The kit of claim 45, wherein said tag sequence does not hybridize to the target sequence.

47. The kit of claim 45, wherein said tag sequence is selected from the following:

(a) SEQ ID NO;

71, (b) SEQ ID NO;

72, (c) SEQ ID NO;

73, (d) SEQ ID NO;

74, (e) SEQ ID NO;

75, (f) SEQ ID NO;

76, (g) SEQ ID NO;

77, (h) SEQ ID NO;

78, (i) SEQ ID NO;

79, (j) SEQ ID NO;

80, (k) SEQ ID NO;

81, (l) SEQ ID NO;

82, (m) SEQ ID NO;

83, (n) SEQ ID NO;

84, (o) SEQ ID NO;

85, (p) SEQ ID NO;

86, (q) SEQ ID NO;

87, (r) SEQ ID NO;

88, (s) SEQ ID NO;

89, (t) SEQ ID NO;

90, (u) SEQ ID NO;

91, (v) SEQ ID NO;

92, (w) SEQ ID NO;

93, (x) SEQ ID NO;

94, (y) SEQ ID NO;

95, (z) SEQ ID NO;

96, (aa) SEQ ID NO;

97, (bb) SEQ ID NO;

98, (cc) SEQ ID NO;

99, (dd) SEQ ID NO;

100, (ee) SEQ ID NO;

101, (ff) SEQ ID NO;

102, (gg) SEQ ID NO;

103, (hh) SEQ ID NO;

104, (ii) SEQ ID NO;

105.

48. A method of detecting levels of at least 2 OXPHOS genes, comprising:

(1) providing one or more target sequences selected from the following;

(a) Mt-Atp6, (b) Mt-Atp8, (c) Mt-Co1, (d) Mt-Co2, (e) Mt-Co3, (f) Mt-Cytb, (g) Mt-Nd1, (h) Mt-Nd2, (i) Mt-Nd3, (j) Mt-Nd4, (k) Mt-Nd41, (l) Mt-Nd5, (m) Mt-Nd61, (n) Atp5a1, (o) Atp5c1, (p) Atp5o, (q) Cox5b, (r) Cox7a2, (s) Cyc1, (t) Hspc051, (u) Ndufa5, (v) Ndufb5, (w) Sdhd, (x) Uqcrb, and (y) Uqcrc1,

(2) providing the plurality of primers that hybridize under stringent conditions to a target sequence from step (1)

(3) amplifying target sequences using primers,

(4) amplifying the sequences of step (3) using 2 nucleic acid sequences that are complementary to at least 1 portion of the primers of step (2), wherein one nucleic acid sequence is linked to a binding moiety, and one nucleic acid sequence is phosphorylated,

(5) identifying the amplification products of step (4) by hybridization to a nucleic acid sequence that is complementary to a portion of the amplification product, wherein nucleic acid sequence is covalently linked to a detectable moiety.

49. The method of claim 48, wherein said amplification products are quantified by binding a second detectable moiety to said binding moiety.

51. The method of claim 51, wherein said detectable moiety is a microsphere.

50. The method of claim 51, wherein said binding moiety is biotin and said second binding moiety is avidin or streptavidin.

52. The method of claim 51, wherein steps (1)-(4) are performed in a microtiter plate.